First Time Loading...
B

Bio-Gene Technology Ltd
ASX:BGT

Watchlist Manager
Bio-Gene Technology Ltd
ASX:BGT
Watchlist
Price: 0.059 AUD -3.28% Market Closed
Updated: May 20, 2024

Intrinsic Value

BGT doesn't have a meaningful market cap.
BGT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Bio-Gene Technology Ltd. is a development company enabling the next generation of novel insecticides, addressing the problems of insecticide resistance and toxicity. [ Read More ]

The intrinsic value of one BGT stock under the Base Case scenario is 0.013 AUD. Compared to the current market price of 0.059 AUD, Bio-Gene Technology Ltd is Overvalued by 79%.

Key Points:
BGT Intrinsic Value
Base Case
0.013 AUD
Overvaluation 79%
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Valuation Backtest
Bio-Gene Technology Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BGT stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Bio-Gene Technology Ltd

Provide an overview of the primary business activities
of Bio-Gene Technology Ltd.

What unique competitive advantages
does Bio-Gene Technology Ltd hold over its rivals?

What risks and challenges
does Bio-Gene Technology Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bio-Gene Technology Ltd.

Provide P/S
for Bio-Gene Technology Ltd.

Provide P/E
for Bio-Gene Technology Ltd.

Provide P/OCF
for Bio-Gene Technology Ltd.

Provide P/FCFE
for Bio-Gene Technology Ltd.

Provide P/B
for Bio-Gene Technology Ltd.

Provide EV/S
for Bio-Gene Technology Ltd.

Provide EV/GP
for Bio-Gene Technology Ltd.

Provide EV/EBITDA
for Bio-Gene Technology Ltd.

Provide EV/EBIT
for Bio-Gene Technology Ltd.

Provide EV/OCF
for Bio-Gene Technology Ltd.

Provide EV/FCFF
for Bio-Gene Technology Ltd.

Provide EV/IC
for Bio-Gene Technology Ltd.

Compare the intrinsic valuations
of Bio-Gene Technology Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bio-Gene Technology Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bio-Gene Technology Ltd compared to its peers.

Compare the P/E ratios
of Bio-Gene Technology Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Bio-Gene Technology Ltd with its peers.

Analyze the financial leverage
of Bio-Gene Technology Ltd compared to its main competitors.

Show all profitability ratios
for Bio-Gene Technology Ltd.

Provide ROE
for Bio-Gene Technology Ltd.

Provide ROA
for Bio-Gene Technology Ltd.

Provide ROIC
for Bio-Gene Technology Ltd.

Provide ROCE
for Bio-Gene Technology Ltd.

Provide Gross Margin
for Bio-Gene Technology Ltd.

Provide Operating Margin
for Bio-Gene Technology Ltd.

Provide Net Margin
for Bio-Gene Technology Ltd.

Provide FCF Margin
for Bio-Gene Technology Ltd.

Show all solvency ratios
for Bio-Gene Technology Ltd.

Provide D/E Ratio
for Bio-Gene Technology Ltd.

Provide D/A Ratio
for Bio-Gene Technology Ltd.

Provide Interest Coverage Ratio
for Bio-Gene Technology Ltd.

Provide Altman Z-Score Ratio
for Bio-Gene Technology Ltd.

Provide Quick Ratio
for Bio-Gene Technology Ltd.

Provide Current Ratio
for Bio-Gene Technology Ltd.

Provide Cash Ratio
for Bio-Gene Technology Ltd.

What is the historical Revenue growth
over the last 5 years for Bio-Gene Technology Ltd?

What is the historical Net Income growth
over the last 5 years for Bio-Gene Technology Ltd?

What is the current Free Cash Flow
of Bio-Gene Technology Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bio-Gene Technology Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bio-Gene Technology Ltd

Current Assets 4.1m
Cash & Short-Term Investments 3.2m
Receivables 557.8k
Other Current Assets 273.5k
Non-Current Assets 234.4k
PP&E 12.8k
Intangibles 221.7k
Current Liabilities 572.9k
Accounts Payable 454.9k
Accrued Liabilities 118k
Non-Current Liabilities 28.7k
Other Non-Current Liabilities 28.7k
Efficiency

Earnings Waterfall
Bio-Gene Technology Ltd

Revenue
761.1k AUD
Operating Expenses
-3.4m AUD
Operating Income
-2.6m AUD
Other Expenses
250 AUD
Net Income
-2.6m AUD

Free Cash Flow Analysis
Bio-Gene Technology Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

BGT Profitability Score
Profitability Due Diligence

Bio-Gene Technology Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
Positive 3-Years Revenue Growth
Declining ROIC
Declining ROE
19/100
Profitability
Score

Bio-Gene Technology Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

BGT Solvency Score
Solvency Due Diligence

Bio-Gene Technology Ltd's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
High Altman Z-Score
77/100
Solvency
Score

Bio-Gene Technology Ltd's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BGT Price Targets Summary
Bio-Gene Technology Ltd

There are no price targets for BGT.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors Analysis
Bio-Gene Technology Ltd

Shareholder Return

BGT Price
Bio-Gene Technology Ltd

1M 1M
-21%
6M 6M
+5%
1Y 1Y
-51%
3Y 3Y
-67%
5Y 5Y
-51%
10Y 10Y
-71%
Annual Price Range
0.059
52w Low
0.038
52w High
0.12
Price Metrics
Average Annual Return 8.71%
Standard Deviation of Annual Returns 59.72%
Max Drawdown -100%
Shares Statistics
Market Capitalization 11.9m AUD
Shares Outstanding 201 362 000
Percentage of Shares Shorted
N/A

BGT Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Bio-Gene Technology Ltd

Country

Australia

Industry

Chemicals

Market Cap

11.9m AUD

Dividend Yield

0%

Description

Bio-Gene Technology Ltd. is a development company enabling the next generation of novel insecticides, addressing the problems of insecticide resistance and toxicity. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-29. The Company’s principal activity is to develop and commercialize insecticide products. The company is focused on enabling novel insecticides to address the global problem of insecticide resistance and toxicity. Its novel platform technology is based on naturally occurring beta-triketones. The Company’s lead beta-triketone insecticide products include Flavocide and Qcide. Flavocide is a synthetically produced nature-identical compound. Testing of Flavocide has been undertaken and continues to be performed by both government research laboratories as well as by commercial collaborators. Qcide natural oil with high levels of tasmanone. The oil is extracted from the leaves of the Gympie Messmate, by utilizing a steam distillation process.

Contact

VICTORIA
Melbourne
Melbourne, Victoria, L 11 456 Lonsdale Street
+61396284178.0
http://bio-gene.com.au/

IPO

2017-11-29

Employees

-

Officers

Interim CFO & Company Secretary
Mr. Roger McPherson B.Bus, C.P.A., CPA, GAICD
Executive Director of Research & Development and Executive Director
Mr. Peter Donald May AFA1M, AFAIM, GAICD, M.B.A., MBA
MD, CEO & Director
Mr. Timothy Owen Grogan B.Sc., LLB

See Also

Discover More
What is the Intrinsic Value of one BGT stock?

The intrinsic value of one BGT stock under the Base Case scenario is 0.013 AUD.

Is BGT stock undervalued or overvalued?

Compared to the current market price of 0.059 AUD, Bio-Gene Technology Ltd is Overvalued by 79%.